AR098739A1 - Análogos del péptido exendina-4 como agonistas duales del receptor de glp-1 / glp (péptido similar al glucagón tipo 1 / glucagón) - Google Patents
Análogos del péptido exendina-4 como agonistas duales del receptor de glp-1 / glp (péptido similar al glucagón tipo 1 / glucagón)Info
- Publication number
- AR098739A1 AR098739A1 ARP140104638A ARP140104638A AR098739A1 AR 098739 A1 AR098739 A1 AR 098739A1 AR P140104638 A ARP140104638 A AR P140104638A AR P140104638 A ARP140104638 A AR P140104638A AR 098739 A1 AR098739 A1 AR 098739A1
- Authority
- AR
- Argentina
- Prior art keywords
- ser
- peptide
- amino acid
- glucagon
- acid residue
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
La presente se refiere a derivados de exendina-4 y a su uso médico, por ejemplo, en el tratamiento de trastornos del síndrome metabólico, que incluyen diabetes y obesidad, además de reducción de la ingesta excesiva de alimentos. Reivindicación 1: Un compuesto peptídico que tiene la fórmula (1): R¹-Z-R² (1) en donde Z es un resto de péptido que tiene la fórmula (2): His-X²-X³-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-GIn-Leu-Asp-Glu-Gln-X¹⁸-Ala-X²⁰-X²¹-Phe-Ile-Glu-Trp-Leu-lle-X²⁸-Gly-Gly-Pro-X³²-Ser-Gly-Ala-Pro-Pro-Pro-Ser (2) X² representa un residuo de aminoácido seleccionado de Ser, D-Ser y Aib, X³ representa un residuo de aminoácido seleccionado de Gln y His, X¹⁸ representa un residuo de aminoácido seleccionado de Arg y Lys, X²⁰ representa un residuo de aminoácido seleccionado de Lys, Gln, His y (S)MeLys, X²¹ representa un residuo de aminoácido seleccionado de Asp y Glu, X²⁸ representa un residuo de aminoácido seleccionado de Ser y Ala, X³² representa un residuo de aminoácido seleccionado de Ser y Val, R¹ representa NH₂, R² representa OH o NH₂, o una sal o solvato del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13306715 | 2013-12-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR098739A1 true AR098739A1 (es) | 2016-06-08 |
Family
ID=49882999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140104638A AR098739A1 (es) | 2013-12-13 | 2014-12-12 | Análogos del péptido exendina-4 como agonistas duales del receptor de glp-1 / glp (péptido similar al glucagón tipo 1 / glucagón) |
Country Status (5)
Country | Link |
---|---|
US (1) | US20170022260A9 (es) |
EP (1) | EP3080155A1 (es) |
AR (1) | AR098739A1 (es) |
TW (1) | TW201609800A (es) |
WO (1) | WO2015086731A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
AU2013366691A1 (en) | 2012-12-21 | 2015-07-09 | Sanofi | Exendin-4 derivatives |
EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/gip受體促效劑 |
TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽-4(exendin-4)胜肽類似物 |
TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/升糖素受體促效劑 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
WO2016198624A1 (en) * | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
WO2016198628A1 (en) * | 2015-06-12 | 2016-12-15 | Sanofi | Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
AU2016379403B2 (en) | 2015-12-23 | 2020-03-12 | The Johns Hopkins University | Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions |
AR110300A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip |
AR110299A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico |
AR110301A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip |
KR20200141469A (ko) | 2018-04-05 | 2020-12-18 | 썬 파마슈티칼 인더스트리스 리미티드 | 신규한 glp-1 유사체 |
ES2928207T3 (es) | 2018-04-10 | 2022-11-16 | Sanofi Aventis Deutschland | Síntesis de lixisenatida con encapuchado |
US11560402B2 (en) | 2018-04-10 | 2023-01-24 | Sanofi-Aventis Deutschland Gmbh | Method for cleavage of solid phase-bound peptides from the solid phase |
UY38249A (es) | 2018-05-30 | 2019-12-31 | Sanofi Sa | Productos conjugados que comprenden un agonista del receptor triple de glp-1/glucagón/gip, un conector y ácido hialurónico |
GB201908424D0 (en) * | 2019-06-12 | 2019-07-24 | Imp College Innovations Ltd | Novel compounds |
CN112409460B (zh) * | 2020-11-27 | 2022-02-01 | 江苏师范大学 | 一类glp-1/胰高血糖素受体双重激动剂及其应用 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050083713A (ko) | 2002-10-02 | 2005-08-26 | 질랜드 파마 에이/에스 | 안정화된 엑센딘-4 화합물 |
JP2008543816A (ja) | 2005-06-13 | 2008-12-04 | インペリアル イノベーションズ リミテッド | 新規化合物および該化合物が摂食行動に及ぼす効果 |
TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
US20090098130A1 (en) * | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
AU2008216265B2 (en) | 2007-02-15 | 2014-04-03 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
JP5385266B2 (ja) | 2007-06-15 | 2014-01-08 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
TWI474835B (zh) * | 2008-06-17 | 2015-03-01 | Univ Indiana Res & Tech Corp | 用於治療代謝病症及肥胖症之基於gip之混合激動劑 |
PE20100255A1 (es) | 2008-06-17 | 2010-04-25 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
UA104605C2 (uk) | 2008-12-15 | 2014-02-25 | Зіленд Фарма А/С | Аналоги глюкагону |
MX2011006320A (es) | 2008-12-15 | 2011-09-22 | Zealand Pharma As | Analogos de glucagon. |
ES2477880T3 (es) | 2008-12-15 | 2014-07-18 | Zealand Pharma A/S | Análogos del glucagón |
DK2370462T3 (da) | 2008-12-15 | 2014-09-08 | Zealand Pharma As | Glucagon-analoger |
WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
DK2454282T3 (en) | 2009-07-13 | 2015-05-04 | Zealand Pharma As | acetylated glucagonanaloger |
US20120148586A1 (en) * | 2009-08-27 | 2012-06-14 | Joyce Ching Tsu Chou | Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders |
US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
EP2552951A1 (en) | 2010-03-26 | 2013-02-06 | Novo Nordisk A/S | Novel glucagon analogues |
AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
JPWO2011152182A1 (ja) | 2010-05-31 | 2013-07-25 | 株式会社ジェイテクト | 被覆部材の製造方法 |
US9252665B2 (en) | 2010-06-01 | 2016-02-02 | Honda Motor Co., Ltd. | DC-DC converter control apparatus |
UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
EA201390941A1 (ru) | 2010-12-22 | 2013-12-30 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Аналоги глюкагона, проявляющие активность на рецепторе gip |
KR20150006052A (ko) * | 2012-05-03 | 2015-01-15 | 질랜드 파마 에이/에스 | 글루카곤-유사 펩타이드-2 (glp-2) 유사체 |
-
2014
- 2014-12-11 EP EP14833135.8A patent/EP3080155A1/en not_active Withdrawn
- 2014-12-11 WO PCT/EP2014/077339 patent/WO2015086731A1/en active Application Filing
- 2014-12-11 TW TW103143204A patent/TW201609800A/zh unknown
- 2014-12-12 US US14/569,326 patent/US20170022260A9/en not_active Abandoned
- 2014-12-12 AR ARP140104638A patent/AR098739A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2015086731A1 (en) | 2015-06-18 |
EP3080155A1 (en) | 2016-10-19 |
TW201609800A (zh) | 2016-03-16 |
US20170022260A9 (en) | 2017-01-26 |
US20160168225A1 (en) | 2016-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR098739A1 (es) | Análogos del péptido exendina-4 como agonistas duales del receptor de glp-1 / glp (péptido similar al glucagón tipo 1 / glucagón) | |
AR098740A1 (es) | Análogos del péptido exendina-4 | |
AR105816A2 (es) | Derivados de exendina-4 funcionalizada | |
AR098736A1 (es) | Análogos del péptido exendina-4 como agonistas duales del receptor del glp-1 / gip (péptido similar al glucagón tipo 1 / polipéptido insulinotrópico dependiente de glucosa) | |
AR098737A1 (es) | Agonistas duales del receptor de glp-1 / gip | |
AR099976A1 (es) | Agonistas peptídicos duales de los receptores de glp-1 / glucagón derivados de la exendina-4 | |
AR099975A1 (es) | Derivados de exendina-4 como agonistas peptídicos duales del receptor de glp-1 / glucagón | |
AR110300A1 (es) | Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip | |
AR098741A1 (es) | Agonistas duales del receptor de glp-1 (péptido similar al glucagón 1) / glucagón | |
AR091866A1 (es) | Analogos del glucagon | |
BR112021023923A2 (pt) | Agonistas de receptor de peptídeo 1 similares a glucagon | |
AR099977A1 (es) | Agonistas peptídicos dobles de los receptores del péptido similar al glucagón 1 (glp-1) y del receptor del glucagón (gcg), derivados de la exendina-4 | |
BR112017008160A8 (pt) | Peptídeo, composição, métodos para tratamento de um paciente ou indivíduo e para tratamento de uma doença metabólica, e, usos de um peptídeo e de uma composição | |
PE20231639A1 (es) | Compuestos co-agonistas del glucagon y peptido-1 similar al glugacon (glp-1) | |
BR112018073511A2 (pt) | polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos | |
CY1116917T1 (el) | Αναλογα οξυντομοντουλινης | |
AR096440A1 (es) | Compuesto peptídico agonista del receptor del péptido similar al glucagón tipo i (glp-1) y del péptido insulinotrópico dependiente de glucosa (gip) | |
AR092925A1 (es) | Derivados de exendina-4 como agonistas duales de glp1 / glucagon | |
AR105284A1 (es) | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón | |
AR098738A1 (es) | Análogos del péptido exendina-4 no acilados | |
AR061242A1 (es) | Polipeptidos de factor de crecimiento de tipo insulina estabilizada | |
AR092873A1 (es) | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon | |
MY156188A (en) | Long - acting formulations of insulins | |
JP2014525901A5 (es) | ||
PE20200606A1 (es) | Composiciones solidas para administracion oral |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |